Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

# PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 79932

**Title:** COVID-19 drug-induced liver injury: A recent update of the literature

**Provenance and peer review**: Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06333260
**Position:** Peer Reviewer
**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Indonesia

**Author's Country/Territory:** India

**Manuscript submission date:** 2022-09-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-09-13 07:37

**Reviewer performed review:** 2022-09-13 07:45

**Review time:** 1 Hour

| | |
|---|---|
| **Scientific quality** | [ ] Grade A: Excellent [ Y] Grade B: Very good [ ] Grade C: Good<br>[ ] Grade D: Fair [ ] Grade E: Do not publish |
| **Language quality** | [ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing<br>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection |
| **Conclusion** | [ ] Accept (High priority) [ Y] Accept (General priority)<br>[ ] Minor revision [ ] Major revision [ ] Rejection |
| **Re-review** | [ Y] Yes [ ] No |
| **Peer-reviewer** | Peer-Review: [ Y] Anonymous [ ] Onymous |

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

| | |
|---|---|
| **statements** | Conflicts-of-Interest: [ ] Yes [ Y] No |

**SPECIFIC COMMENTS TO AUTHORS**

The manuscript is clear and explicit. I have no comment to contribute.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

# PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 79932

**Title:** COVID-19 drug-induced liver injury: A recent update of the literature

**Provenance and peer review**: Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05573818
**Position:** Peer Reviewer
**Academic degree:** MD, PhD
**Professional title:** Chief Doctor, Surgeon
**Reviewer's Country/Territory:** China
**Author's Country/Territory:** India

**Manuscript submission date:** 2022-09-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-09-13 03:57

**Reviewer performed review:** 2022-09-19 16:23

**Review time:** 6 Days and 12 Hours

| | |
|---|---|
| **Scientific quality** | [ ] Grade A: Excellent [ Y] Grade B: Very good [ ] Grade C: Good<br>[ ] Grade D: Fair [ ] Grade E: Do not publish |
| **Language quality** | [ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing<br>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection |
| **Conclusion** | [ ] Accept (High priority) [ Y] Accept (General priority)<br>[ ] Minor revision [ ] Major revision [ ] Rejection |
| **Re-review** | [ ] Yes [ Y] No |
| **Peer-reviewer** | Peer-Review: [ Y] Anonymous [ ] Onymous |

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

| | |
|---|---|
| **statements** | Conflicts-of-Interest: [ ] Yes [ Y] No |

**SPECIFIC COMMENTS TO AUTHORS**

1. COVID-19 is now spreading around the world. The proportion of liver damage in these patients is relatively high. At present, the mechanism of its occurrence is not clear. This article analyzes the possible causes of liver damage in new coronary pneumonia and related drugs from multiple perspectives, It is a hot spot of concern and has certain clinical reference value. 2. The overall quality of the article is high, the expression is concise and clear, and the main points of the analysis are comprehensive. The article also put forward t different opinions on the mechanism of liver damage in patients with COVID-19, which is innovative; 3. The research background part of the introduction is too long and can be appropriately simplified; 4. The article mentions that "it is difficult to assess the liver toxicity of drugs used in new coronary pneumonia, because many drugs are used off-label and in doses that are not routinely used" and "reports of DILI may be rarely encountered in the routine treatment of some drugs, but may be more frequent when used in new coronary pneumonia", but the text only This paper analyzes the situation of liver damage caused by some commonly used drugs, whether it can increase the analysis of liver damage after some off-label drugs, and whether it can compare the different situations of liver damage caused by different drug dosages. Of course, this can be the next thing to be done; 5. The full text adopts the method of data analysis to analyze The situation of liver damage in patients with COVID-19 , but the amount of data is slightly insufficient, and the logic of the entire article is slightly lacking, and the connections between the various sections are not close enough.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

# PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 79932

**Title:** COVID-19 drug-induced liver injury: A recent update of the literature

**Provenance and peer review**: Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06284599
**Position:** Peer Reviewer
**Academic degree:** MD, PhD
**Professional title:** Associate Chief Physician
**Reviewer's Country/Territory:** China
**Author's Country/Territory:** India

**Manuscript submission date:** 2022-09-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-09-13 15:57

**Reviewer performed review:** 2022-09-21 09:19

**Review time:** 7 Days and 17 Hours

| | |
|---|---|
| **Scientific quality** | [ ] Grade A: Excellent [ Y] Grade B: Very good [ ] Grade C: Good<br>[ ] Grade D: Fair [ ] Grade E: Do not publish |
| **Language quality** | [ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing<br>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection |
| **Conclusion** | [ ] Accept (High priority) [ ] Accept (General priority)<br>[ Y] Minor revision [ ] Major revision [ ] Rejection |
| **Re-review** | [ ] Yes [ Y] No |
| **Peer-reviewer** | Peer-Review: [ Y] Anonymous [ ] Onymous |

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
**Telephone:** +1-925-399-1568
**E-mail:** bpgoffice@wjgnet.com
**https**://www.wjgnet.com

| | |
|---|---|
| **statements** | Conflicts-of-Interest: [ ] Yes [ Y] No |

**SPECIFIC COMMENTS TO AUTHORS**

This review is summarised that the general situation and potential mechanisms of liver injury caused by COVID-19, and how to manage liver injury in COVID-19 patients. More importantly, authors are focusing on the liver injury induced by drug in COVID-19 patients. It is a unique perspective. As there are very less studies or researches about liver damage caused by drug in COVID-19 patients, the diagnosis is by exclusion and the treatment is not certain. However, the treatment should be more detailed in this paper that could be very helpful for doctors and patients. Furthermore, the points of view of a few references is inaccurate. Lastly, the structure and logic could be more rational.